EP Vantage PD-1/PD-L1 Combination Therapies report
PD-1/PD-L1 Combinations Drive the Development Of New Immunotherapies
Copyright © 2015, Evaluate Ltd, All rights reserved.
EPVantage-PD1-PDL1-Combination-Therapies-Cover.png EPVantage-PD1-PDL1-Combination-Therapies-P1.png EPVantage-PD1-PDL1-Combination-Therapies-P2.png

The immuno-oncology agents Keytruda and Opdivo have already transformed the cancer care landscape.

Now specialists are pairing them with approved or experimental agents to improve on their already impressive efficacy, according to EP Vantage’s PD-1/PD-L1 Combination Therapies report.

Key highlights include:

  • More than half of the agents paired with PD-1 and PD-L1 projects are small molecules, chemotherapies and established drugs.

  • Yervoy is the most widely studied monoclonal antibody combination agent.

  • Lung cancer and melanoma remain the two most popular indications for combination products.

  • A number of products including atezolizumab and durvalumab are already being tested in combination, even before achieving approval from the FDA or European Medicines Agency.

  • Older therapies such as oncolytic viruses and vaccines that have so far disappointed as monotherapies might benefit from the combination approach.

Download your copy of the report: